Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis

INTRODUCTION: The ASTRUM-005 trial (NCT04063163) revealed that combination serplulimab plus chemotherapy (etoposide and carboplatin [EC]) treatment was associated with survival advantages relative to chemotherapy alone in patients diagnosed with extensive-stage small-cell lung cancer (ES-SCLC). As t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Youwen, Liu, Kun, Qin, Qun, Zhu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845593/
https://www.ncbi.nlm.nih.gov/pubmed/36685541
http://dx.doi.org/10.3389/fimmu.2022.1044678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845593/
https://www.ncbi.nlm.nih.gov/pubmed/36685541
http://dx.doi.org/10.3389/fimmu.2022.1044678

Ejemplares similares